Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Andrew P. Schachat, MD, is the Vice Chairman for Clinical Affairs at the Cole Eye Institute, Cleveland Clinic, and Director of Clinical Research. He is the former Karl Hagen Professor of Ophthalmology, Vice Chairman for Safety and Quality of the Department of Ophthalmology, and Director of the Ocular Oncology Service, at Johns Hopkins University. He was also Professor of Oncology.
In 2003, Dr. Schachat became Editor-in-Chief of the American Academy of Ophthalmology’s journal, Ophthalmology.
He was born in New York City, attended Princeton University, graduating in 1975, and then medical school at Johns Hopkins University, graduating in 1979. His ophthalmology residency training was at the Wilmer Institute at Johns Hopkins, and his retina and oncology fellowship was at the Wills Eye Hospital in Philadelphia. In 1984, he was Assistant Chief of Service at Wilmer.
He was for five years Secretary of Quality of Care for the American Academy of Ophthalmology, and in 2001, President of the Maryland Society of Eye Physicians and Surgeons. He is a former Associate Editor of the Archives of Ophthalmology and a current Editor of two volumes of Ryan’s Retina, 4th Edition, 2006.
age-related macular degeneration, clinical trials, Diabetic retinopathy
Awards & Honors
- Former Karl Hagen Professor of Ophthalmology, Johns Hopkins University
- Long record of grants/research funding
- Included in various "best" lists
- Summa cum laude (chemistry)
- Sigma Xi
- William Foster Memorial Prize
- Merck Index Award
Johns Hopkins University School of Medicine:
- Phi Beta Kappa
- Alpha Omega Alpha
- USPHS NIH Research Grant recipient
- Heed Ophthalmic Foundation Fellowship, 1982-1983
- Heed-Knapp Fellowship, 1983
- American Academy of Ophthalmology Senior Honor Award, 1998
- American Academy of Ophthalmology Honor Award, 1989
Innovations & Patents
Has been a principal investigator in most studies that have led to new FDA-approved therapies for age-related macular degeneration.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/4/2015, Dr. Schachat has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.